Ohio House Bill 501 was introduced March 20, 2014 to place Zohydro on the Schedule I list which would prohibit APRN prescription.
Zohydro™ ER is an opioid agonist, extended-release, oral formulation of hydrocodone bitartrate indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. While this drug has stirred controversy nationwide, Zohydro has its place for intractable pain and hospice patients.
OAAPN is asking Ohio APRNs, who manage these populations, if the restriction of Zohydro will impact their ability to provide services.
Please respond to info@oaapn.org with comments no later than 4/15/2014.